Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Accumulated Expenses for 7 consecutive years, with $21.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 5897.47% to $21.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.4 million, a 5897.47% increase, with the full-year FY2025 number at $21.4 million, up 5897.47% from a year prior.
  • Other Accumulated Expenses was $21.4 million for Q4 2025 at Kymera Therapeutics, up from $14.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $21.4 million in Q4 2025 to a low of $117000.0 in Q2 2025.
  • A 5-year average of $5.1 million and a median of $875500.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 96.08% in 2021, then surged 7345.18% in 2022.
  • Kymera Therapeutics' Other Accumulated Expenses stood at $228000.0 in 2021, then soared by 7345.18% to $17.0 million in 2022, then plummeted by 78.3% to $3.7 million in 2023, then crashed by 90.34% to $356000.0 in 2024, then surged by 5897.47% to $21.4 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Other Accumulated Expenses are $21.4 million (Q4 2025), $14.6 million (Q3 2025), and $117000.0 (Q2 2025).